The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

Brigimadlin (BI 907828) is an oral MDM2–p53 antagonist that has shown encouraging antitumor activity in vivo. We present phase Ia results from an open-label, first-in-human, phase Ia/Ib study investigating brigimadlin in patients with advanced solid tumors (NCT03449381). Fifty-four patients received...

Descripción completa

Detalles Bibliográficos
Autores principales: LoRusso, Patricia, Yamamoto, Noboru, Patel, Manish R., Laurie, Scott A., Bauer, Todd M., Geng, Junxian, Davenport, Teffany, Teufel, Michael, Li, Jian, Lahmar, Mehdi, Gounder, Mrinal M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401071/
https://www.ncbi.nlm.nih.gov/pubmed/37269344
http://dx.doi.org/10.1158/2159-8290.CD-23-0153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401071/
https://www.ncbi.nlm.nih.gov/pubmed/37269344
http://dx.doi.org/10.1158/2159-8290.CD-23-0153

Ejemplares similares